首页> 外文期刊>International Research Journal of Medical Sciences >Immunohistochemical Expression of Fn14 in invasive Ductal Carcinoma (IDC) and its Correlation with Clinical and Histopathological parameters of Human Breast cancer
【24h】

Immunohistochemical Expression of Fn14 in invasive Ductal Carcinoma (IDC) and its Correlation with Clinical and Histopathological parameters of Human Breast cancer

机译:Fn14在浸润性导管癌(IDC)中的免疫组织化学表达及其与人乳腺癌临床和组织病理学参数的关系

获取原文
获取外文期刊封面目录资料

摘要

Fibroblast growth factor-inducible 14 (Fn14), is a member of the tumor necrosis factor receptor superfamily that normally expressed in healthy tissues, but its expression is increased in injured tissue where it thought to play role in tissue remodeling. Over expression of Fn14 expression is reported in many tumors, which is why this protein is under consideration as a therapeutic target in oncology.The aim of the present work was to investigate the expression of Fn14 as a novel prognostic biomarker in human invasive ductal carcinoma (IDC) versus benign tumors and normal breast tissues as well as their correlation with different pathological and histological parameters. Immunohistochemical technique was used to examine the expression of Fn14 in normal, benign as well as in IDC. Present results showed higher expression of Fn14 in IDC comparing to normal and benign breast tissues. Statistical analysis showed significant correlations between the expression of Fn14 and histological tumor grade, lymph node metastasis (LNM) and HER2eu. Negative correlation was noticed between the expression of Fn14 and both ER and PR status. Current results suggest that Fn14 protein may be a valuable prognostic and therapeutic marker inhuman IDC pateints.
机译:成纤维细胞生长因子诱导型14(Fn14)是正常在健康组织中表达的肿瘤坏死因子受体超家族的成员,但在受伤组织中的表达增加,认为在组织重塑中发挥作用。在许多肿瘤中都报告了Fn14表达的过度表达,这就是为什么该蛋白被认为是肿瘤学中的治疗靶标的原因。 IDC)与良性肿瘤和正常乳腺组织的关系,以及它们与不同病理和组织学参数的相关性。免疫组织化学技术用于检测Fn14在正常,良性以及IDC中的表达。目前的结果显示,与正常和良性乳腺组织相比,IDC中Fn14的表达更高。统计分析表明Fn14的表达与组织学肿瘤分级,淋巴结转移(LNM)和HER2 / neu之间存在显着相关性。 Fn14的表达与ER和PR状态呈负相关。目前的结果表明,Fn14蛋白可能是人类IDC患者的有价值的预后和治疗标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号